Cubist Systematic Strategies LLC Sells 64,847 Shares of LifeMD, Inc. (NASDAQ:LFMD)

Cubist Systematic Strategies LLC lessened its holdings in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 31.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 139,042 shares of the company's stock after selling 64,847 shares during the quarter. Cubist Systematic Strategies LLC owned 0.32% of LifeMD worth $688,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in LFMD. Prudential Financial Inc. increased its stake in LifeMD by 19.3% in the 4th quarter. Prudential Financial Inc. now owns 13,605 shares of the company's stock valued at $67,000 after buying an additional 2,200 shares during the last quarter. Rhumbline Advisers increased its position in shares of LifeMD by 6.1% during the 4th quarter. Rhumbline Advisers now owns 48,689 shares of the company's stock valued at $241,000 after purchasing an additional 2,814 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in LifeMD by 26.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock valued at $70,000 after buying an additional 2,895 shares during the period. Geode Capital Management LLC grew its position in LifeMD by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 822,217 shares of the company's stock worth $4,071,000 after acquiring an additional 2,984 shares during the last quarter. Finally, Magnus Financial Group LLC raised its holdings in LifeMD by 31.1% during the 4th quarter. Magnus Financial Group LLC now owns 16,000 shares of the company's stock valued at $79,000 after buying an additional 3,792 shares during the last quarter. Institutional investors and hedge funds own 35.52% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LFMD. HC Wainwright restated a "buy" rating and issued a $14.00 price target on shares of LifeMD in a research note on Wednesday, April 30th. B. Riley upgraded LifeMD to a "strong-buy" rating in a research report on Tuesday, March 11th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $15.00 price target on shares of LifeMD in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $11.00.

Insider Buying and Selling

In other news, CMO Jessica Friedeman sold 30,000 shares of the business's stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $5.66, for a total transaction of $169,800.00. Following the completion of the transaction, the chief marketing officer now directly owns 170,000 shares in the company, valued at approximately $962,200. The trade was a 15.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Justin Schreiber sold 50,000 shares of LifeMD stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $7.78, for a total value of $389,000.00. Following the sale, the chief executive officer now directly owns 2,575,721 shares of the company's stock, valued at $20,039,109.38. This represents a 1.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,995 shares of company stock valued at $724,422 in the last quarter. Company insiders own 15.97% of the company's stock.

LifeMD Trading Up 4.1%

LFMD traded up $0.44 on Wednesday, hitting $11.08. 427,945 shares of the company's stock were exchanged, compared to its average volume of 1,440,520. The firm has a 50-day moving average price of $6.51 and a 200-day moving average price of $5.95. The stock has a market cap of $503.38 million, a price-to-earnings ratio of -17.27 and a beta of 2.22. LifeMD, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $11.21.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.05. The company had revenue of $65.70 million during the quarter, compared to analyst estimates of $62.47 million. On average, equities analysts predict that LifeMD, Inc. will post -0.56 EPS for the current year.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.